Protein Kinase A as a Promising Target for Heart Failure Drug Development

Arch Med Res. 2018 Nov;49(8):530-537. doi: 10.1016/j.arcmed.2018.12.008. Epub 2019 Jan 11.

Abstract

Heart failure (HF) is a clinical syndrome characterized by impaired ability of the heart to fill or eject blood. HF is rather prevalent and it represents the foremost reason of hospitalization in the United States. The costs linked to HF overrun those of all other causes of disabilities, and death in the United States and all over the developed as well as the developing countries which amplify the supreme significance of its prevention. Protein kinase (PK) A plays multiple roles in heart functions including, contraction, metabolism, ion fluxes, and gene transcription. Altered PKA activity is likely to cause the progression to cardiomyopathy and HF. Thus, this review is intended to focus on the roles of PKA and PKA-mediated signal transduction in the healthy heart as well as during the development of HF. Furthermore, the impact of cardiac PKA inhibition/activation will be highlighted to identify PKA as a potential target for the HF drug development.

Keywords: Cardiac hypertrophy; Cardiac muscle; Heart failure; PKA; PKA inhibitors.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Calcium / metabolism
  • Cardiomyopathies / pathology*
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Disease Progression
  • Drug Development
  • Heart / physiology*
  • Heart Failure / pathology*
  • Humans
  • Myocardium / pathology*
  • Signal Transduction / physiology

Substances

  • Cyclic AMP-Dependent Protein Kinases
  • Calcium